1 published article · Updated continuously
6 trials tracked for palmoplantar pustulosis: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 114 citations.
Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Apremilast has demonstrated significant efficacy in treating Palmoplantar Pustulosis. In a Phase 3 trial, patients treated with Apremilast showed a statistically significant reduction in PPPASI total scores at week 16 compared to baseline (p<0.0001) and achieved a high rate of success in reaching the PPPASI-50 threshold (67.8% vs 35.3%, p<0.0001). Further evidence from a Phase 2 trial confirmed significant improvements in PPPASI scores by week 20 (p<0.0001).
Guselkumab also demonstrated statistically significant reductions in PPPASI total scores at week 16 (p<0.001) and showed measurable changes in the Palmoplantar Severity Index (PPSI) at week 16.
AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
